Mycobacterium phlei cell wall-nucleic acid complex in the treatment of nonmuscle invasive bladder cancer unresponsive to bacillus Calmette-Guerin

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Expert Opinion on Biological Therapy

• Publication date

  2016-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1517/14712598.2016.1134483PMID 26865049
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics

  2015cited by this paper
• Combining Mitomycin C and Regional 70 MHz Hyperthermia in Patients with Nonmuscle Invasive Bladder Cancer: A Pilot Study.

  2015cited by this paper
• The effectiveness of BCG and interferon against non‐muscle invasive bladder cancer: a New Zealand perspective

  2015cited by this paper
• Single instillation of mitomycin C plus bacillus Calmette-Guérin (BCG) versus BCG alone in high grade non-muscle invasive bladder cancer.

  2015cited by this paper
• Cancer statistics, 2015

  2015cited by this paper
• Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guérin.

  2015cited by this paper
• Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies

  2014cited by this paper
• Contemporary cost‐effectiveness analysis comparing sequential bacillus Calmette‐Guerin and electromotive mitomycin versus bacillus Calmette‐Guerin alone for patients with high‐risk non–muscle‐invasive bladder cancer

  2014cited by this paper
• Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy.

  2013cited by this paper
• Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer.

  2013cited by this paper
• SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin.

  2013cited by this paper
• New agents for bacillus Calmette-Guérin-refractory bladder cancer.

  2013cited by this paper
• A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guérin.

  2012cited by this paper
• Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial.

  2012cited by this paper
• The health economics of bladder cancer

  2012cited by this paper
• Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer.

  2012cited by this paper
• A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer.

  2012cited by this paper
• Intravesical gemcitabine therapy for non‐muscle invasive bladder cancer (NMIBC): a systematic review

  2012cited by this paper
• 1783 SAFETY OF INTRAVESICAL MYCOBACTERIAL CELL WALL-DNA COMPLEX GIVEN IMMEDIATELY POSTSURGERY IN PATIENTS WITH NON-MUSCLE-INVASIVE BLADDER CANCER

  2012cited by this paper
• A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guérin refractory nonmuscle invasive bladder cancer.

  2011cited by this paper
• The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review.

  2011cited by this paper
• Co‐administration of intravesical bacillus Calmette‐Guérin and interferon α‐2B as first line in treating superficial transitional cell carcinoma of the urinary bladder a

  2011cited by this paper
• Projections of the cost of cancer care in the United States: 2010-2020.

  2011cited by this paper
• The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer.

  2010cited by this paper
• Challenging the EAU Guidelines on Non–Muscle-Invasive Bladder Cancer (NMIBC): Single Instillation of Chemotherapy After Transurethral Resection of NMIBC and Chemotherapy Versus Bacillus Calmette-Guérin in Treatment of Intermediate-Risk Tumours

  2010cited by this paper
• Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance.

  2010cited by this paper
• Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed.

  2009cited by this paper
• Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin.

  2009cited by this paper
• Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy.

  2008cited by this paper
• A critical analysis of perioperative mortality from radical cystectomy.

  2006cited by this paper
• Management of BCG failures in superficial bladder cancer: a review.

  2006cited by this paper
• Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials.

  2005cited by this paper
• Management of bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer: results with intravesical BCG and Interferon combination therapy.

  2003cited by this paper
• Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.

  2003cited by this paper
• Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity.

  2003influential reference
• Defining bacillus Calmette-Guerin refractory superficial bladder tumors.

  2003cited by this paper
• Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.

  2002influential reference
• Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials.

  2002cited by this paper
• Therapeutic potential of mycobacterial cell wall-DNA complexes

  2001cited by this paper
• The mycobacteria: an introduction to nomenclature and pathogenesis.

  2001influential reference
• Pro‐apoptotic and immunomodulatory activity of a mycobacterial cell wall‐DNA complex towards LNCaP prostate cancer cells

  2001cited by this paper
• Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder.

  2001cited by this paper
• Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed.

  2001cited by this paper
• What are the immunologically active components of Bacille Calmette‐Guérin in therapy of superficial bladder cancer?

  2000cited by this paper
• The changing pattern of mortality and morbidity from radical cystectomy

  2000cited by this paper
• Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.

  2000influential reference
• Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group.

  2000cited by this paper
• Modulation of interleukin-12 synthesis by DNA lacking the CpG motif and present in a mycobacterial cell wall complex

  2000cited by this paper
• EFFICACY AND SAFETY OF VALRUBICIN FOR THE TREATMENT OF BACILLUS CALMETTE-GUERIN REFRACTORY CARCINOMA IN SITU OF THE BLADDER

  2000influential reference
• Mycobacterium phlei cell wall complex directly induces apoptosis in human bladder cancer cells

  1999cited by this paper
• Extravesical tumor relapse in patients with superficial bladder tumors.

  1998cited by this paper
• Determination of mycobacterial phylogeny on the basis of immunological relatedness of superoxide dismutases.

  1996influential reference
• Mycobacterium cell wall: an alternative to intravesical bacillus Calmette Guerin (BCG) therapy in orthotopic murine bladder cancer.

  1996cited by this paper
• Immunotherapy of an experimental adenocarcinoma of the prostate.

  1995cited by this paper
• Cancer statistics

  1989cited by this paper
• Intravesical administration of bacillus Calmette-Guérin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial.

  1985cited by this paper
• Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer.

  1980cited by this paper
• Treatment of carcinoma in situ of the bladder with BCG

  1980cited by this paper
• Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors.

  1976cited by this paper
• IMMUNOTHERAPY WITH NONVIABLE MICROBIAL COMPONENTS

  1976cited by this paper
• INTRACAVITARY BACILLUS CALMETTE‐GUERIN IN THE TREATMENT OF SUPERFICIAL BLADDER TUMORS

  1976cited by this paper
• Immunotherapy of cancer: tumor suppression and regression by cell walls of Mycobacterium phlei attached to oil droplets.

  1975cited by this paper
• Immunologic reduction of bladder cancer recurrence rate.

  1974cited by this paper
• Immunologic reduction of bladder cancer recurrence rate.

  1974cited by this paper

• Evaluation of the cross-immunity between Mycobacterium tuberculosis and Mycobacterium abscessus in vitro

  2025cites this paper
• Mycobacteria Treatment Inhibits Bladder Cancer Cell Migration, Invasion, and Anchorage-Independent Growth

  2024cites this paper
• Research progress into the application of Mycobacterium phlei in veterinary medicine

  2023cites this paper
• Proteomic networks associated with tumor-educated macrophage polarization and cytotoxicity potentiated by heat-killed tuberculosis

  2022cites this paper
• New Roadmaps for Non-muscle-invasive Bladder Cancer With Unfavorable Prognosis

  2020cites this paper
• At a time of global BCG shortage, attempts at optimizing BCG dose and schedule is no longer the answer.

  2020cites this paper
• Sex Differences in Bladder Cancer Immunobiology and Outcomes: A Collaborative Review with Implications for Treatment.

  2020cites this paper
• Investigating the STING Pathway to Explain Mechanisms of BCG Failures in Non-Muscle Invasive Bladder Cancer: Prognostic and Therapeutic Implications

  2019cites this paper
• Immunotherapy in nonmuscle invasive bladder cancer: current and emerging treatments

  2019cites this paper
• Novel Agents in BCG Refractory Disease

  2019cites this paper
• Effects of an immune stimulant, inactivated Mycobacterium phlei, on the growth performance as well as meat quality of fattening pigs.

  2018cites this paper
• Emerging intravesical drugs for the treatment of non muscle-invasive bladder cancer

  2018cites this paper
• Mycobacteria-Derived Agents for the Treatment of Urological and Renal Cancers

  2017cites this paper
• BCG: A throwback from the stone age of vaccines opened the path for bladder cancer immunotherapy.

  2017cites this paper
• The in Vitro and in Vivo Anti-Cancer Potential of Mycobacterium Cell Wall Fraction (MCWF) Against Canine Transitional Cell Carcinoma of the Urinary Bladder

  2017cites this paper
• Bladder cancer: Advancing NMIBC treatment beyond current BCG formulations

  2016cites this paper
• Administration of Mycobacterium phlei cell wall-nucleic acid complex in the immediate postoperative period for the treatment of non-muscle-invasive bladder cancer.

  2016cites this paper
• Recent advances in immuno‐oncology and its application to urological cancers

  2016cites this paper